Actualités et Activités de Foundation Medicine
Présence
Roche fait partie des...
- Forbes Global 2000 (#80);
- Fortune 500 Europe (#44);
- Russell 3000;
- Stoxx 600;
- Swiss market index;
- TOB Iconic 10,000.
Roche est une société cotée sous le symbole boursier ROG (CH).
Roche a une présence directe dans 21 pays.Roche a 37 filiales dont Cenexi, Chugai Pharmaceutical et Flatiron Health.
Elles sont en:
- Pharmacie66%
- Biotechnologie29%
- Autre5%
Acquisition, funding and merger involving Roche.
- Poseida Therapeutics and Roche have merged (publié le 28 novembre 2024)..
- Roche has announced the acquisition of Carmot Therapeutics (publié le 7 décembre 2023).
Dirigeants
Voir l'organigramme avec ses 11 principaux dirigeants
Biographies les plus recherchées chez Foundation Medicine
- Dan Malarek, Chief Executive Officer
- Jennifer Romans, Senior Vice President, Corporate Affairs
- Lucas Dennis, Senior Vice President and Head of Research and Deve...
Changements de dirigeants chez Roche
- Wafaa Mamilli rejoindra l'entreprise comme Member of the Executive Committee and Chief Digital Technology Officer le 10 févr. 2025 (publié le 29 janvier 2025).
Créer une alerte
pour suivre les mouvements de dirigeants chez Foundation Medicine.
Biotechnologie
Roche a 2 351 concurrents dont Astellas Gene Therapies (Etats—Unis), Eurofins (Luxembourg) et BitBiome (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Draig Therapeutics vient d'annoncer une levée de fonds de 140 millions de dollars. (publié le 18 juin 2025).
- Eli Lilly has announced the acquisition of Verve Therapeutics (publié le 17 juin 2025).
- Sirius Therapeutics vient d'annoncer une levée de fonds de 50 millions de dollars. (publié le 16 juin 2025).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Foundation Medicine
- Foundation Medicine Awards Grants to Organizations Addressing Disparities in Biomarker Testing for Breast and Prostate Cancer
- U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® (tepotinib) to Identify Patients with MET Exon 14 Skipping Alterations in Non-Small Cell Lung Cancer
- U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
- Foundation Medicine Awarded Contract by the U.S. Department of Veterans Affairs to Provide Tumor Molecular Profiling to Veterans with Cancer
- U.S. Food and Drug Administration Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Lynparza® (olaparib) in Combination with Abiraterone for Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
- Foundation Medicine Partners with Syndax to Develop a Companion Diagnostic in Hematology and Support Efforts to Pursue Regulatory Approval for an Assay Based on the FoundationOne®Heme Platform
- Foundation Medicine Collaborates with Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine’s RNA Platform
- U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for AKEEGA® (niraparib and abiraterone acetate) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
- Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
- Foundation Medicine Launches RNA Sequencing Test, FoundationOne®RNA, in the U.S.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Foundation Medicine
- Foundation Medicine sur Wikipédia, Google News & Yahoo Finance en 1-click
- Foundation Medicine sur LinkedIn, Twitter & YouTube en 1-click
